PROF

Profound MedicalC

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$9.50

+46.6% vs current

Most likely

Base case

50%

Probability

Target price

$7.25

+11.9% vs current

B-

Bear case

25%

Probability

Target price

$4.25

-34.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-18

AI commentary

Sentiment is neutral-to-cautious. The evidence base is primarily filing-driven, not news-driven, and the deterministic prior is neutral with only middling evidence quality. The 10-K supports real revenue progress and adequate near-term liquidity, but forward visibility still looks limited enough that this remains a monitoring memo rather than a strong directional call.

RankAlpha Sentiment Codex - 2026-04-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07eventQ1 2026 results and business update on May 7, 2026High impact

Profound said on April 16, 2026 that it plans to release first-quarter 2026 financial results after market close on May 7, 2026 and host a call the same day; this is the next hard read-through on TULSA-PRO placement and utilization trends [#8-K-2026-04-16].

2026-12-31catalystTULSA-PRO recurring revenue conversion remains the core operating proof pointHigh impact

The 10-K says Profound uses a hybrid model with capital sales plus one-time-use devices and services, is building direct sales teams to increase utilization, and expects recurring revenues from devices, clinical support and maintenance; 2025 revenue was $16.1M, including $9.73M recurring non-capital revenue versus $8.24M in 2024, which supports a commercialization-monitoring thesis rather than a breakout thesis [#10-K-2026-03-05].

2027-03-05catalystCash runway reduces near-term financing pressure but does not remove execution riskHigh impact

Profound ended 2025 with $59.7M of cash after December 2025 equity raises and said existing cash plus product sales should fund operating expenses and capex for at least 12 months from the March 5, 2026 filing date; that de-risks immediate dilution, but the company also posted a $40.3M net loss and higher commercialization spending, so investors still need to see operating leverage [#10-K-2026-03-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-18 • Updated nightlySource: Internal modelMethodology